Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,229,113
  • Shares Outstanding, K 14,544
  • Annual Sales, $ 200 K
  • Annual Income, $ 1,688 M
  • EBIT $ -192 M
  • EBITDA $ -189 M
  • 60-Month Beta 1.18
  • Price/Sales 6,464.08
  • Price/Cash Flow 0.76
  • Price/Book 34.96

Options Overview Details

View History
  • Implied Volatility 148.41% (+4.05%)
  • Historical Volatility 51.24%
  • IV Percentile 72%
  • IV Rank 24.61%
  • IV High 373.04% on 10/22/25
  • IV Low 75.06% on 03/24/25
  • Expected Move (DTE 8) 13.52 (16.00%)
  • Put/Call Vol Ratio 0.46
  • Today's Volume 162
  • Volume Avg (30-Day) 868
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 16,235
  • Open Int (30-Day) 26,218
  • Expected Range 70.95 to 97.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.84
  • Growth Rate Est. (year over year) +35,276.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.00 +17.06%
on 11/13/25
94.47 -10.79%
on 12/08/25
+6.44 (+8.27%)
since 11/11/25
3-Month
26.19 +221.80%
on 09/17/25
94.47 -10.79%
on 12/08/25
+55.83 (+196.24%)
since 09/11/25
52-Week
10.81 +680.01%
on 04/11/25
94.47 -10.79%
on 12/08/25
+69.16 (+457.41%)
since 12/11/24

Most Recent Stories

More News
Inhibrx Reports Third Quarter 2025 Financial Results

SAN DIEGO , Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion...

INBX : 84.32 (-0.22%)
Inhibrx Announces Participation in Upcoming Scientific Conferences

SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic...

INBX : 84.32 (-0.22%)
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

SAN DIEGO , Oct. 23, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for...

INBX : 84.32 (-0.22%)
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

– Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT –

INBX : 84.32 (-0.22%)
Inhibrx Reports Second Quarter 2025 Financial Results

SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following...

INBX : 84.32 (-0.22%)
Inhibrx Announces Participation in Upcoming Scientific Conferences

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

INBX : 84.32 (-0.22%)
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

INBX : 84.32 (-0.22%)
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a...

INBX : 84.32 (-0.22%)
Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in development and a strong...

INBX : 84.32 (-0.22%)
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with four clinical programs in development and a strong...

INBX : 84.32 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 102.34
2nd Resistance Point 96.57
1st Resistance Point 90.54
Last Price 84.32
1st Support Level 78.74
2nd Support Level 72.97
3rd Support Level 66.94

See More

52-Week High 94.47
Last Price 84.32
Fibonacci 61.8% 62.51
Fibonacci 50% 52.64
Fibonacci 38.2% 42.77
52-Week Low 10.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar